Compare Gemini Space Station Inc (GEMI) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance

Gemini Space Station IncTrade

Recursion Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

Gemini Space Station Inc vs Recursion Pharmaceuticals Inc — how do they compare? Gemini Space Station Inc trades at $4.02 (market cap $512.05M), while Recursion Pharmaceuticals Inc trades at $3.35 (market cap $1.81B). The key difference: Recursion Pharmaceuticals Inc is far larger — about 3.5× Gemini Space Station Inc's market cap, and Recursion Pharmaceuticals Inc is trading nearer its 52-week high, Gemini Space Station Inc nearer its low. Which is the better fit depends on your goals.

	GEMI	RXRX
Market Cap	$512.05M	$1.81B
Sector	Technology	Health
52-Week High	$32.52	$6.79
52-Week Low	$3.90	$2.84
Enterprise Value	$502.04M	$1.33B

View details →View details →

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

GEMI

NYC Council probes deceptive marketing by prediction market platforms amid legal battles.CNBC · 5 hours agoBearish View details →

RXRX

Recursion Pharmaceuticals faces slow growth and cash burn despite AI drug discovery partnerships.Seeking Alpha · 1 day agoBearish View details →

About Gemini Space Station Inc

Gemini Space Station Inc is the parent company of the Gemini crypto ecosystem, founded by Cameron and Tyler Winklevoss. It operates as a regulated digital asset exchange and custodian, providing a platform for individuals and institutions to trade, store, and stake cryptocurrencies while serving as a trusted bridge between legacy finance and the decentralized web.

About Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.